NCT05361356 is a NA clinical trial of Spectral CT scanning in Adult ALL, sponsored by Philips (China) Investment CO., LTD.

Who is sponsoring NCT05361356?

NCT05361356 is sponsored by Philips (China) Investment CO., LTD.

What drugs are being tested in NCT05361356?

Interventions in NCT05361356: Spectral CT scanning.

Is NCT05361356 still recruiting?

NCT05361356 is currently terminated. Last updated 7 April 2023.

Last reviewed 2023-04-07 · How we verify

NCT05361356

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spectral CT Clinical Trial

Terminated NA Last updated 7 April 2023

What this trial tests

NA trial testing Spectral CT scanning in Adult ALL in 56 participants. Terminated before completion.

Timeline

10 March 2022

Primary endpoint
19 October 2022

27 February 2023

Quick facts

Lead sponsor	Philips (China) Investment CO., LTD
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	56
Start date	10 March 2022
Primary completion	19 October 2022
Estimated completion	27 February 2023
Sites	3 locations across China

Drugs / interventions tested

Spectral CT scanning

Conditions studied

Adult ALL — all drugs for Adult ALL →

Sponsor

Philips (China) Investment CO., LTD

Who can join

Adults 18 to 75, any sex, with Adult ALL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this clinical trial was to evaluate the efficacy, ease of operation, stability, and safety of Spectral CT as expected.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Adult ALL

Currently open trials in the same condition.

NCT06386861 — Validating the Spanish "Attitudes Toward Genomics and Precision Medicine" (AGPM). · NA · active not recruiting
NCT06220487 — A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With New · Phase 2 · recruiting

Other Philips (China) Investment CO., LTD trials

Trials by the same sponsor.

NCT06095479 — Ultrasound Liver Fat Quantification on Pediatric Patients · NA · completed
NCT05017233 — Spectral CT Clinical Trial Protocol · NA · terminated
NCT04519489 — The Efficacy of PAP Therapy on Reducing AF Recurrence in Patients With Morbidity of OSA · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05361356 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Philips (China) Investment CO., LTD
Last refreshed: 7 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05361356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing